WallStSmart
VEEV

Veeva Systems Inc Class A

NYSE: VEEV · HEALTHCARE · HEALTH INFORMATION SERVICES

$155.97
-1.42% today

Updated 2026-04-30

Market cap
$26.01B
P/E ratio
29.08
P/S ratio
8.14x
EPS (TTM)
$5.44
Dividend yield
—
52W range
$148 – $311
Volume
2.1M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Veeva Systems Inc Class A (VEEV) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$155.97
Consensus
$284.00
+82.09%
2030 Target
$434.95
+178.87%
DCF
$296.62
+40.31% MoS
26 analysts:
12 Buy8 Hold1 Sell

Management guidance

Veeva management has publicly stated a goal of reaching a $6 billion revenue run rate by 2030, implying ~$5.8B-$6.0B in FY2030 revenue. CEO guidance at Q4 FY2026 earnings (March 2026) provided FY2027 revenue guidance of $3.59B-$3.60B (midpoint $3.595B), representing ~12.3% growth from FY2026's $3.20B. This guidance exceeded Wall Street consensus, indicating management confidence in mid-to-high single-digit growth acceleration.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$713.32
$5.9B Rev × 20x P/S
Base case (2030)
$434.95
$5.9B Rev × 12x P/S
Bear case (2030)
$295.77
$5.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2024202520262027 (E)2028 (E)2029 (E)2030 (E)
Revenue$2.4B$2.7B$3.2B$3.6B$4.1B$4.7B$5.9B
Revenue growth—16.2%16.3%12.3%11.8%14.0%26.9%
EPS$4.84$6.00$8.06$8.76$9.99$11.85$15.20
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$260.97$295.77$347.96$434.95

Catalysts & risks

Growth catalysts
+ Vault CRM migration acceleration (125+ customers live, agentic AI transformation)
+ Veeva AI platform monetization and customer adoption across Vault products
+ Ostro acquisition integration ($100M deal for brand engagement AI platform in life sciences)
+ Industry Cloud expansion driving higher net dollar retention and upsells
+ $2 billion share repurchase program supporting EPS accretion
Key risks
- CRM migration execution risk and customer churn during platform transition
- AI competition from larger enterprise software vendors (Salesforce, Microsoft, Oracle, Adobe)
- Valuation multiple compression if growth decelerates below 10% sustainably
- Life sciences pharma/biotech sector consolidation reducing customer count
- Macro slowdown in healthcare IT spending affecting subscription renewal rates

Methodology

Veeva Systems Inc Class A's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 26 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.